-
Change in metabolic tumor activity on F-18-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.
Van Helden, E. J., Menke, C. W., Boon, E., van Es, S., Huisman, M. C., De Groot, D. J., Boellaard, R., Van Herpen, C. M. L., De Vries, E., Hoekstra, O. S. & Verheul, H. M. W., 20 May 2017, In: Journal of clinical oncology. 35Research output: Contribution to journal › Article* › Academic › peer-review
-
A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or piatinum-resistant ovarian cancer (OC)
Weekes, C. D., Lamberts, L. E., Borad, M. J., Voortman, J., McWilliams, R. R., Diamond, J. R., De Vries, E., Verheul, H. M. W., Lieu, C. H., Yue, H., Wang, Y., Scales, S., Samineni, D., Wood, K., Brunstein, F., Maslyar, D. J. & Kim, G. P., 20 May 2014, In: Journal of clinical oncology. 32, 15Research output: Contribution to journal › Meeting Abstract › Academic
- All publications
